Literature DB >> 2569054

Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.

H Gurney1, R Kefford, R Stuart-Harris.   

Abstract

The effect of a single dose of pamidronate was studied in 15 patients with hypercalcaemia of malignancy. All patients were hydrated with saline 24 h before and 48 h after treatment. The dose of pamidronate was 30-90 mg intravenously, depending on corrected calcium level after hydration. Patients were retrospectively divided into two groups according to response to pamidronate. Corrected calcium fell to normal or below the upper limit of normal within a median of 3 days after treatment in 7 well controlled patients. In 8 poorly controlled patients corrected calcium failed to return to normal and in 7 of these, corrected calcium increased within 8 days of treatment. The best single indicator of a potent renal mechanism for the hypercalcaemia and also a poor response to pamidronate was a low renal phosphate threshold. Negative isotopic bone scans were also more common in poorly controlled patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569054     DOI: 10.1016/s0140-6736(89)90429-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  7 in total

1.  Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.

Authors:  S J Gallacher; S H Ralston; F J Dryburgh; F C Logue; B F Allam; B F Boyce; I T Boyle
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

Review 2.  Medical management of hypercalcaemia.

Authors:  S H Ralston
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 3.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

4.  Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.

Authors:  S H Ralston; D Thiébaud; Z Herrmann; E U Steinhauer; B Thürlimann; J Walls; M R Lichinitser; R Rizzoll; H Hagberg; H J Huss; M Tubiana-Hulin; J J Body
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 5.  Hypercalcemia in malignancy.

Authors:  G J Strewler; R A Nissenson
Journal:  West J Med       Date:  1990-12

6.  Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.

Authors:  S J Gallacher; W D Fraser; F C Logue; F J Dryburgh; R A Cowan; I T Boyle; S H Ralston
Journal:  Calcif Tissue Int       Date:  1992-12       Impact factor: 4.333

7.  [Pamidronate in the treatment of tumor-associated hypercalcemia].

Authors:  M Pecherstorfer; S Janisch; C Marosi; C Wogritsch; C Bosse; W Schratzberger; E Gerber; A Fortelny; R Lenzhofer; H Rainer
Journal:  Klin Wochenschr       Date:  1991-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.